BerGenBio

BerGenBio to Present at the Carnegie Nordic Healthcare Conference

BERGEN, Norway, March 16, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, today announced that Martin Olin, Chief Executive

Officer of BerGenBio, will present at the Carnegie Nordic Healthcare Conference

in Stockholm, Sweden, today March 16, 2023, at 1:45 pm CET.

The presentation will be made available on the Company website in the

Investor/presentations section at time of presentation:

www.bergenbio.com/investors/presentations/

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

Investor Relations / Media Relations

Graham Morrell

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal